Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02945813
Recruitment Status : Recruiting
First Posted : October 26, 2016
Last Update Posted : July 11, 2019
Sponsor:
Information provided by (Responsible Party):
Swiss Group for Clinical Cancer Research

Brief Summary:
The main objective of the trial is to explore the efficacy of salvage radiotherapy (SRT) plus metformin compared to SRT in the endpoint of time to progression after prostatectomy failure.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: Metformin Radiation: Salvage Radiotherapy SRT Phase 2

Detailed Description:
Although the use of salvage radiotherapy (SRT) is the only potentially curative treatment after prostatectomy failure, it has provided suboptimal results over the years. Metformin may represent an effective and inexpensive means to improve SRT outcomes with a favorable therapeutic ratio. Taken pre-clinical and retrospective clinical data together, there is a compelling rationale for conducting a RCT with SRT and metformin. Herein we propose a multicenter, randomized, open-label, proof-of-concept phase II trial with the hypothesis that the addition of metformin to SRT can delay time to progression compared to the standard-of-care SRT. The study has 1:1 randomization and stratification variables include Gleason score, PSA at SRT, surgical margin status and ADT use.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 170 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: SAKK 08/15 - PROMET - Multicenter, Randomized Phase II Trial of Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy
Actual Study Start Date : October 24, 2017
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2030

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: Arm A: Metformin
  • Metformin - 850mg PO BID; 48 weeks
  • Salvage radiotherapy SRT - 35 x 2Gy; 7 weeks
Drug: Metformin
850mg PO BID; 48 weeks

Radiation: Salvage Radiotherapy SRT
SRT 35 x 2Gy; 7 weeks

Active Comparator: Arm B: Salvage Radiotherapy
- Salvage radiotherapy SRT - 35 x 2Gy; 7 weeks
Radiation: Salvage Radiotherapy SRT
SRT 35 x 2Gy; 7 weeks




Primary Outcome Measures :
  1. Time to progression (TTP) [ Time Frame: within 18 months after randomization ]

    The primary endpoint of the trial is time to progression (TTP), defined as time from randomization until one of the following events, whichever comes first:

    • Biochemical progression
    • Clinical progression
    • Death due to clinical progression


Secondary Outcome Measures :
  1. Progression free survival (PFS) [ Time Frame: within 18 months after randomization ]

    PFS is defined as time from randomization until one of the following events, whichever comes first:

    • Biochemical progression
    • Clinical progression
    • Death from any cause

  2. Undetectable Prostate Specific Antigen (PSA) under normal testosterone levels [ Time Frame: up to 18 months after last radiotherapy fraction ]
    Undetectable PSA is defined as a serum PSA value of ≤0.05 ng/mL for at least two consecutive measurements after the last radiotherapy fraction and up to 18 months thereafter. To count as undetectable PSA under normal testosterone levels, the testosterone level has to be ≥50 ng/dL (i.e. a non-castrate testosterone level).

  3. 50% PSA response [ Time Frame: at randomization up to 18 months after last radiotherapy fraction. ]
    50% PSA response is defined as a ≥50% PSA decline after radiotherapy compared to the serum PSA level at randomization up to 18 months after last radiotherapy fraction.

  4. Clinical progression-free survival [ Time Frame: week 64 then every 6 months for the first year and every 12 months thereafter up to 10 years from last RT fraction. ]
    Clinical progression-free survival will be calculated as the time from randomization until clinical progression or death due to any cause.

  5. Time to further anti-cancer systemic therapy [ Time Frame: week 64 then every 6 months for the first year and every 12 months thereafter up to 10 years from last RT fraction. ]
    Time to further anti-cancer systemic therapy (e.g. hormonal treatment) is defined as the time from randomization to the start of any type of salvage systemic treatment.

  6. Prostate cancer-specific survival (PCSS) [ Time Frame: at week 64 then every 6 months for the first year and every 12 months thereafter up to 10 years from last RT fraction. ]
    Prostate cancer-specific survival will be calculated as the time from randomization to the date of death due to prostate cancer.

  7. Overall survival (OS) [ Time Frame: at week 64 then every 6 months for the first year and every 12 months thereafter up to 10 years from last RT fraction. ]
    Overall survival will be calculated as the time from randomization to the date of death from any cause.

  8. Adverse Events (AE) [ Time Frame: until 56 weeks (specific RT-related AEs : until 10 years) ]
    AEs will be assessed according to NCI CTCAE v4.03.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent according to ICH/GCP regulations before registration and prior to any trial specific procedures
  • Histologically confirmed adenocarcinoma of the prostate without small cell features
  • Tumor stage pT2a-3b, pN0 or cN0, M0, R0-1 resection margins, according to UICC TNM 2009, Gleason score available
  • Radical prostatectomy (RP) at least 12 weeks before registration
  • PSA progression after RP defined as two consecutive rises with the final PSA > 0.1 ng/mL or three consecutive rises. The first value must be measured earliest 4 weeks after RP
  • PSA ≤ 2 ng/mL within 14 days prior to registration
  • Age ≥ 18 years at time of registration
  • WHO performance status 0-1
  • Adequate hepatic function within 14 days prior to registration: bilirubin ≤ 1.5 x ULN (exception if Gilbert's syndrome ≤ 3 x ULN), AST and ALT ≤ 2.5 x ULN
  • Adequate renal function within 14 days prior to registration: calculated corrected creatinine clearance ≥ 60 mL/min, according to the formula of corrected Cockcroft-Gault Patient agrees not to father a child and to use effective contraceptive methods during salvage radiotherapy and until 6 months after the last fraction of radiotherapy

Exclusion Criteria:

  • Persistent PSA (> 0.4 ng/mL) 4 to 20 weeks after RP
  • Pelvic lymph node enlargement > 0.8 cm in short axis diameter (cN positive) assessed by mpMRI within 12 weeks prior to registration, unless the enlarged lymph node is sampled and negative
  • Evidence of macroscopic local recurrence assessed by mpMRI within 12 weeks prior to registration
  • Palpable prostatic fossa mass suggestive of recurrence, unless an ultrasound guided biopsy is negative for malignancy
  • Presence or history of prostate cancer metastases. In case of clinical suspicion (e.g. bone pain), imaging (e.g. bone scan, Choline-PET, PSMA-PET, whole body MRI) must be performed. The imaging method is at the discretion of the investigator.
  • If PET/CT scan was performed, any metabolic uptake considered clinically suspicious for malignancy, unless biopsy proves to be negative.
  • History of hematologic or primary solid tumor malignancy, unless in remission for at least 3 years from registration with the exception of curatively treated localized non-melanoma skin cancer
  • Patients diagnosed with diabetes mellitus
  • Treatment with metformin within the last 3 months prior to registration
  • Prior pelvic radiotherapy
  • Hormonal treatment as bilateral orchiectomy prior or following RP
  • Usage of products known to affect PSA levels within 4 weeks prior to start of trial treatment
  • Bilateral hip prosthesis
  • Severe or active co-morbidity likely to impact on the advisability of salvage RT, e.g.:

    • History of inflammatory bowel disease or any malabsorption syndrome or conditions that would interfere with enteral absorption
    • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
    • Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
    • Transmural myocardial infarction within the last 6 months
    • Chronic Obstructive Pulmonary Disease (COPD) exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
  • Any condition associated with increased risk of lactic acidosis (e.g. alcohol abuse, congestive heart failure NYHA III or IV
  • Clinically significant history of liver disease consistent with Child-Pugh Class B or C, including viral or other hepatitis, current alcohol abuse, or cirrhosis
  • Severe or uncontrolled kidney disease resulted in impaired kidney function (GFR <60ml/min)
  • Any acute or chronic condition that could cause tissue hypoxia (e.g. cardiac or respiratory insufficiency, recent myocardial infarction, shock)
  • Treatment with any experimental drug or participation within a clinical trial within 30 days prior to registration (exception: concurrent participation in the biobank project SAKK 63/12 is allowed)
  • Any concomitant drug contraindicated for use with metformin according to the approved product information
  • Known hypersensitivity to metformin/placebo or to any of its components
  • Hereditary intolerance to fructose; known galactose-1-phosphate uridyl transferase deficiency, UDP galactose 4 epimerase deficiency, galactokinase deficiency, Fanconi-Bickel syndrome, congenital lactase deficiency, or glucose-galactose malabsorption (due to the lactose-containing placebo)
  • Inability or unwillingness to swallow oral medication
  • Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02945813


Contacts
Layout table for location contacts
Contact: Daniele Oberti, PhD +41 31 389 91 91 trials@sakk.ch

Locations
Layout table for location information
France
Centre Hospitalier Régional Universitaire (CHRU) Jean Minjoz Not yet recruiting
Besançon, France, 25030
Contact: Bernardino De Bari, MD    +33 381 23 24 28    bdebari@chu-besancon.fr   
Principal Investigator: Bernardino De Bari         
Clinique Pasteur - Centre finistérien de radiothérapie et d'oncologie Not yet recruiting
Brest, France, 29220
Contact: Ali Hasbini, MD    +33 298 31 32 00    alihasbini@oncologie-brest.fr   
Principal Investigator: Ali Hasbini, MD         
Centre de lutte contre le cancer Léon Bérard Recruiting
Lyon, France, 69008
Contact: Pascal Pommer, MD    +33 478 78 51 66    pascal.pommier@lyon.unicancer.fr   
Principal Investigator: Pascal Pommer, MD         
Hôpital Saint-Louis Not yet recruiting
Paris, France, 75010
Contact: Christophe Hennequin, Prof    +33 142 49 90 24    christophe.hennequin2@aphp.fr   
Principal Investigator: Christophe Hennequin, Prof         
CHU de Poitiers - La Miletrie Not yet recruiting
Poitiers Cedex, France, 86021
Contact: Stéphane Guerif, MD    +33 549 44 29 61    stephane.guerif@chu-poitiers.fr   
Principal Investigator: Stéphane Guerif, MD         
Institut de Cancérologie de L'Ouest René Gauducheau Recruiting
Saint Herblain cedex, France, 44800
Contact: Stéphane Supiot, MD    +33 240 679 913    stephane.supiot@ico.unicancer.fr   
Principal Investigator: Stéphane Supiot, MD         
Institut de Cancérologie de la Loire Lucien Neuwirth Recruiting
Saint Priest en Jarez, France, 42270
Contact: Nicolas Magne, Prof    +33 477 91 71 04    nicolas.magne@icloire.fr   
Principal Investigator: Nicolas Magne, Prof         
Clinique Pasteur - Oncorad Recruiting
Toulouse Cedex 3, France, 31076
Contact: Igor Latorzeff, MD    +33 567 20 44 00    ilatorzeff@clinique-pasteur.com   
Principal Investigator: Igor Latorzeff, MD         
Germany
Universitätsmedizin Berlin Recruiting
Berlin, Germany, 13353
Contact: Pirus Ghadjar, MD    +49 450 657055    pirus.ghadjar@charite.de   
Principal Investigator: Pirus Ghadjar, MD         
Klinikum der Universität München Not yet recruiting
München, Germany, 81377
Contact: Claus Belka, Prof    +49 89 4400 74520    claus.belka@med.uni-muenchen.de   
Principal Investigator: Claus Belka, Prof         
Universitätsklinikum Rostock Recruiting
Rostock, Germany, 18059
Contact: Guido Hildebrandt, Prof    +49 381 494 90 00    guido.hildebrandt@uni-rostock.de   
Principal Investigator: Guido Hildebrandt, Prof         
Universitätsklinik Tübingen Recruiting
Tübingen, Germany, 72076
Contact: Arndt-Christian Müller, MD    +49 70 712 98 61 43    arndt-christian.mueller@med.uni-tuebingen.de   
Principal Investigator: Arndt-Christian Müller, MD         
Universitätsklinikum Würzburg Recruiting
Würzburg, Germany, 97080
Contact: Michael Flentje, Prof    +49 931 201 288 91    flentje_m@ukw.de   
Principal Investigator: Michael Flentje, Prof         
Switzerland
Universitätsspital Basel Recruiting
Basel, Switzerland, 4031
Contact: Alexandros Papachristofilou, MD    +41 61 265 49 46    alexandros.papachristofilou@usb.ch   
Principal Investigator: Alexandros Papachristofilou, MD         
EOC-Istituto Oncologico della Svizzera Italiana Recruiting
Bellinzona, Switzerland, 6500
Contact: Davide Giovanni Bosetti, MD    +41 91 811 81 76    DavideGiovanni.Bosetti@eoc.ch   
Principal Investigator: Davide Giovanni Bosetti, MD         
Inselspital Bern Recruiting
Bern, Switzerland, 3010
Contact: Daniel Aebersold, Prof    +41 31 632 26 32    daniel.aebersold@insel.ch   
Principal Investigator: Daniel Aebersold, Prof         
Kantonsspital Graubuenden Recruiting
Chur, Switzerland, 7000
Contact: Richard Cathomas, MD    +41 81 256 66 46    richard.cathomas@ksgr.ch   
Principal Investigator: Richard Cathomas, MD         
HFR - Hôpital cantonal Recruiting
Fribourg, Switzerland, 1708
Contact: David Lauffer, MD    +41 26 306 00 00    David.Lauffer@h-fr.ch   
Principal Investigator: David Lauffer, MD         
Hôpitaux Universitaires Genève HUG Recruiting
Geneva, Switzerland, 1211
Contact: Thomas Zilli, MD    +41 22 372 70 90    thomas.zilli@hcuge.ch   
Principal Investigator: Thomas Zilli, MD         
Clinique de Genolier Recruiting
Genolier, Switzerland, 1272
Contact: Cristina Picardi, MD    +41 22 366 94 59    cpicardi@genolier.net   
Principal Investigator: Cristina Picardi, MD         
Spital Thurgau Recruiting
Münsterlingen, Switzerland, CH-8596
Contact: Christiane Reuter, MD    +41 71 686 23 33    christiane.reuter@stgag.ch   
Principal Investigator: Christiane Reuter, MD         
Hopital de Sion Recruiting
Sion, Switzerland, 1951
Contact: Kaouthar Khanfir, MD    +41 27 603 87 72    kaouthar.khanfir@hopitalvs.ch   
Principal Investigator: Kaouthar Khanfir, MD         
Kantonsspital St. Gallen Recruiting
St. Gallen, Switzerland, 9007
Contact: Paul Martin Putora, MD    +41 71 494 22 68    paulmartin.putora@kssg.ch   
Principal Investigator: Paul Martin Putora, MD         
Kantonsspital Winterthur KSW Not yet recruiting
Winterthur, Switzerland, 8401
Contact: Binaya Kumar Shrestha, MD    +41 52 266 55 05    binayakumar.shrestha@ksw.ch   
Principal Investigator: Binaya Kumar Shrestha, MD         
Klinik Hirslanden Recruiting
Zurich, Switzerland, 8032
Contact: Marcin Sumila, MD    +41 44 387 25 51    marcin.sumila@hirslanden.ch   
Principal Investigator: Marcin Sumila, MD         
Stadtspital Triemli Recruiting
Zurich, Switzerland, 8063
Contact: Kathrin Zaugg, MD    +41 44 416 35 50    kathrin.zaugg@triemli.zuerich.ch   
Principal Investigator: Kathrin Zaugg, MD         
UniversitätsSpital Zürich Recruiting
Zurich, Switzerland, 8091
Contact: Matthias Guckenberger, Prof    +41 44 255 29 30    Matthias.Guckenberger@usz.ch   
Principal Investigator: Matthias Guckenberger, Prof         
Sponsors and Collaborators
Swiss Group for Clinical Cancer Research
Investigators
Layout table for investigator information
Study Chair: Daniel M. Aebersold, Prof Bern University Hospital - Radiation Oncology
Study Chair: Alan Dal Pra, MD Miller School of Medicine, University of Miami

Layout table for additonal information
Responsible Party: Swiss Group for Clinical Cancer Research
ClinicalTrials.gov Identifier: NCT02945813     History of Changes
Other Study ID Numbers: SAKK 08/15 - PROMET
2016‐003599‐39 ( EudraCT Number )
First Posted: October 26, 2016    Key Record Dates
Last Update Posted: July 11, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Swiss Group for Clinical Cancer Research:
Prostate Cancer
Prostate Cancer after Prostatectomy
Phase II Trial
Salvage Radiotherapy
Metformin

Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Metformin
Hypoglycemic Agents
Physiological Effects of Drugs